

CITATION REPORT

List of articles citing

Controlled-release phentermine/topiramate in severely obese adults: a randomized controlled trial (EQUIP)

DOI: 10.1038/oby.2011.330
Obesity, 2012, 20, 330-42.

Source: <https://exaly.com/paper-pdf/53170280/citation-report.pdf>

Version: 2024-04-28

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
443	A review of topiramate and phentermine: a combined therapeutic approach for obesity. 2012 , 7, 13-25		6
442	Phentermine plus topiramate for the treatment of obesity. 2012 , 7, 503-510		1
441	New medications for weight loss. 2012 , 25, 59-60		
440	Zonisamide for weight reduction in obese adults: a 1-year randomized controlled trial. 2012 , 172, 1557-64		48
439	Psychopharmacologic treatment of obesity and eating disorders in children and adolescents. 2012 , 21, 831-59		8
438	A Review of the Combination of Phentermine and Topiramate Extended-Release for Weight Loss. 2012 , 2, 1		3
437	Limitations in anti-obesity drug development: the critical role of hunger-promoting neurons. 2012 , 11, 675-91		148
436	Journal of Diabetes NEWS. 2012 , 4, 197-202		
435	Phentermine and topiramate extended release (Qsymia) [®] first global approval. 2012 , 72, 2033-42		21
434	Obesity and the Cardiorenal Metabolic Syndrome: Therapeutic Modalities and Their Efficacy in Improving Cardiovascular and Renal Risk Factors. 2012 , 2, 314-327		17
433	Pharmacological management of binge eating disorder: current and emerging treatment options. 2012 , 8, 219-41		49
432	Phentermine/Topiramate Extended Release. 2012 , 47, 950-958		
431	Carbonic anhydrase inhibitors as emerging drugs for the treatment of obesity. 2012 , 17, 11-5		67
430	A Role for Emerging Obesity Drugs. 2012 , 6, 185-187		2
429	The impact of weight loss among seniors on Medicare spending. 2013 , 3, 7		12
428	Evaluation of lorcaserin for the treatment of obesity. 2013 , 9, 1053-9		10
427	The central question of type 2 diabetes. 2013 , 2, 399-427		1

426	The effect of orlistat on body weight in obese Czech adults. 2013 , 8, 553-557	
425	Pharmacologic treatment options for obesity: what is old is new again. 2013 , 15, 182-9	26
424	Obesity and Black Women: Special Considerations Related to Genesis and Therapeutic Approaches. 2013 , 7, 378-386	32
423	Changes in cardiovascular risk associated with phentermine and topiramate extended-release in participants with comorbidities and a body mass index ≥ 7 kg/m ² . 2013 , 111, 1131-8	23
422	A long journey to effective obesity treatments: is there light at the end of the tunnel?. 2013 , 238, 491-501	10
421	New obesity agents: lorcaserin and phentermine/topiramate. 2013 , 47, 1007-16	57
420	New options for the treatment of obesity and type 2 diabetes mellitus (narrative review). 2013 , 27, 508-18	34
419	American Association of Clinical Endocrinologists' Comprehensive Diabetes Management Algorithm 2013 Consensus Statement. 2013 , 19, 1-48	102
418	Topiramate: Effects on cognition in patients with epilepsy, migraine headache and obesity. 2013 , 6, 211-27	47
417	Obesity, adiposity, and dyslipidemia: a consensus statement from the National Lipid Association. 2013 , 7, 304-83	241
416	Fixed-dose combination of phentermine-topiramate for the treatment of obesity. 2013 , 6, 235-41	8
415	Evaluation of phentermine and topiramate versus phentermine/topiramate extended-release in obese adults. <i>Obesity</i> , 2013 , 21, 2163-71	8 133
414	Phentermine and topiramate extended-release: a new treatment for obesity and its role in a complications-centric approach to obesity medical management. 2013 , 12, 741-56	15
413	Antiobesity pharmacotherapy: new drugs and emerging targets. 2014 , 95, 53-66	123
412	Pharmacotherapy for childhood obesity: present and future prospects. 2013 , 37, 1-15	45
411	Therapy of obese patients with cardiovascular disease. 2013 , 13, 200-4	9
410	Weight Loss in the Management of Obstructive Sleep Apnea. 2013 , 8, 517-525	
409	American Association of Clinical Endocrinologists' comprehensive diabetes management algorithm 2013 consensus statement--executive summary. 2013 , 19, 536-57	196

408	Obesity: A Focus on Pharmacotherapy. 2013 , 9, 387-395	1
407	Update on treatment strategies for obesity. 2013 , 98, 1299-306	49
406	New and emerging pharmacologic therapies for type 2 diabetes, dyslipidemia, and obesity. 2013 , 35, A3-17	19
405	New pharmacological approaches for obesity management. 2013 , 9, 467-78	42
404	Gut hormones and obesity: physiology and therapies. 2013 , 91, 143-94	16
403	Reducing the risk of obesity: defining the role of weight loss drugs. 2013 , 33, 1308-21	11
402	Pharmacotherapy. 2013 , 99-108	
401	Guidelines updates in the treatment of obesity or metabolic syndrome and hypertension. 2013 , 15, 196-203	22
400	Glucagon-like peptide-1 receptor agonists for weight loss in adult patients without diabetes. 2013 , 70, 2097-103	19
399	Severe obesity: Introductory outlines and the conventional non surgical therapy. 2013 , 8, e216-e227	2
398	Phentermine/topiramate for the treatment of obesity. 2013 , 47, 340-9	43
397	Long-lasting improvements in liver fat and metabolism despite body weight regain after dietary weight loss. 2013 , 36, 3786-92	38
396	Novel metabolic drugs and blood pressure: implications for the treatment of obese hypertensive patients?. 2013 , 15, 470-4	5
395	Can neuropeptides treat obesity? A review of neuropeptides and their potential role in the treatment of obesity. 2013 , 170, 1333-48	24
394	Management of Obesity in Older People. 2013 , 43, 145-149	
393	Pharmacotherapy of obesity: clinical treatments and considerations. 2013 , 345, 284-288	98
392	Role of the gastroenterologist in managing obesity. 2013 , 7, 439-51	21
391	Treatment of the obese patient in primary care: targeting and meeting goals and expectations. 2013 , 125, 67-77	20

390	Drug treatment of obesity in the cardiovascular patient. 2013 , 28, 584-91		2
389	New medications for obesity management: changing the landscape of obesity treatment. 2013 , 20, 407-11		10
388	A complications-based clinical staging of obesity to guide treatment modality and intensity. 2013 , 20, 377-88		42
387	Severe obesity in children and adolescents: identification, associated health risks, and treatment approaches: a scientific statement from the American Heart Association. 2013 , 128, 1689-712		640
386	Ascending dose-controlled trial of beloranib, a novel obesity treatment for safety, tolerability, and weight loss in obese women. <i>Obesity</i> , 2013 , 21, 1782-8	8	48
385	Clinical utility of phentermine/topiramate (Qsymia) combination for the treatment of obesity. 2013 , 6, 131-9		19
384	Phentermine and topiramate for the management of obesity: a review. 2013 , 7, 267-78		14
383	New tools for weight-loss therapy enable a more robust medical model for obesity treatment: rationale for a complications-centric approach. 2013 , 19, 864-74		51
382	Lipoprotein subfractions in metabolic syndrome and obesity: clinical significance and therapeutic approaches. 2013 , 5, 928-48		92
381	Lorcaserin for weight management. 2013 , 6, 209-16		11
380	Pharmacotherapy for obesity. 2014 , 20, 90-6		22
379	Combination phentermine and topiramate for weight maintenance: the first Australian experience. 2014 , 201, 224-6		10
378	Optimal Pharmacologic Treatment Strategies in Obesity and Type 2 Diabetes. 2014 , 3, 595-613		7
377	Antiobesity pharmacotherapy for patients with type 2 diabetes: focus on long-term management. 2014 , 29, 410-7		11
376	American association of clinical endocrinologists and american college of endocrinology consensus conference on obesity: building an evidence base for comprehensive action. 2014 , 20, 956-76		28
375	Prevention of type 2 diabetes in subjects with prediabetes and metabolic syndrome treated with phentermine and topiramate extended release. 2014 , 37, 912-21		130
374	Current pharmacotherapy for obesity: extrapolation of clinical trials data to practice. 2014 , 15, 809-22		20
373	Novel anti-obesity drugs and plasma lipids. 2014 , 9, 179-187		7

372	Can medical therapy mimic the clinical efficacy or physiological effects of bariatric surgery?. 2014 , 38, 325-33	47
371	Obesity management: applying clinical trial data to clinical care. 2014 , 20 Suppl 2, 6-19	1
370	Bariatric endocrinology: principles of medical practice. 2014 , 2014, 917813	13
369	Efficacy and safety of the adjustable gastric band - pooled interim analysis of the APEX and HERO studies at 48 weeks. 2014 , 30, 841-8	1
368	New centrally acting agents for appetite control: from biological mechanisms to clinical efficacy. 2014 , 30, 961-9	3
367	Update on obesity pharmacotherapy. 2014 , 1311, 1-13	59
366	Weight-loss therapy in type 2 diabetes: effects of phentermine and topiramate extended release. 2014 , 37, 3309-16	78
365	Modern obesity pharmacotherapy: weighing cardiovascular risk and benefit. 2014 , 37, 693-9	25
364	Cardiovascular effects of phentermine and topiramate: a new drug combination for the treatment of obesity. 2014 , 32, 1178-88	47
363	New antiobesity agents: lorcaserin (Belviq) and phentermine/topiramate ER (Qsymia). 2014 , 22, 43-50	10
362	Recent advances in clinical practice challenges and opportunities in the management of obesity. 2014 , 63, 687-95	67
361	Pharmacotherapy considerations in diabetes and obesity: setting patients up for success. 2014 , 126, 100-9	4
360	Combination phentermine/topiramate for obesity treatment in primary care: a review. 2014 , 126, 110-6	4
359	Combining clinical judgment with guidelines for the management of type 2 diabetes: overall standards of comprehensive care. 2014 , 126, 85-94	5
358	New and emerging drug molecules against obesity. 2014 , 19, 65-76	48
357	Neues und praktisch Relevantes aus der gynkologischen Endokrinologie. 2014 , 12, 51-54	
356	Naltrexone/bupropion for obesity: an investigational combination pharmacotherapy for weight loss. 2014 , 84, 1-11	89
355	New pharmacological treatments for the management of obesity. 2014 , 16, 394	25

354	Pharmacotherapy for obesity: novel agents and paradigms. 2014 , 5, 135-48		68
353	Pharmacotherapy for Obesity. 2014 , 261-277		
352	Long-term drug treatment for obesity: a systematic and clinical review. 2014 , 311, 74-86		535
351	Weight loss strategies for treatment of obesity. 2014 , 56, 465-72		132
350	Managing overweight and obesity in adults to reduce cardiovascular disease risk. 2014 , 16, 445		34
349	Tolerability and safety of the new anti-obesity medications. 2014 , 37, 693-702		59
348	Meta- and cost-effectiveness analysis of commercial weight loss strategies. <i>Obesity</i> , 2014 , 22, 1942-51	8	105
347	Medical treatment of obesity: the past, the present and the future. 2014 , 28, 665-84		58
346	An evolving scientific basis for the prevention and treatment of pediatric obesity. 2014 , 38, 887-905		73
345	Dental considerations for patients taking weight-loss medications. 2014 , 145, 70-4		3
344	Anti-Obesity Agents and the US Food and Drug Administration. 2014 , 3, 361-7		
343	Quantifying energy intake changes during obesity pharmacotherapy. <i>Obesity</i> , 2014 , 22, 2105-8	8	11
342	Pharmacotherapy for weight loss: the cardiovascular effects of the old and new agents. 2014 , 39, 475-84		5
341	Antiepileptic drugs and hormones. 65-79		
340	Management of obesity and cardiometabolic risk - role of phentermine/extended release topiramate. 2014 , 7, 35-44		14
339	Tools for Successful Weight Management in Primary Care. 2015 , 350, 485-97		3
338	Current and emerging medications for overweight or obesity in people with comorbidities. 2015 , 17, 1021-32		48
337	American Association Of Clinical Endocrinologists And American College Of Endocrinology -Clinical Practice Guidelines For Developing A Diabetes Mellitus Comprehensive Care Plan 2015. 2015 , 21, 1-87		390

336	Obesity medications: what does the future look like?. 2015 , 22, 360-6	14
335	Anti-obesity drugs. 2015 , 26, 536-43	21
334	CONSENSUS STATEMENT BY THE AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY ON THE COMPREHENSIVE TYPE 2 DIABETES MANAGEMENT ALGORITHM--2015 EXECUTIVE SUMMARY. 2015 , 21, 1403-14	20
333	Weight Loss Pharmacotherapy: Brief Summary of the Clinical Literature and Comments on Racial Differences. 2015 , 25, 511-4	6
332	Recent Advances for Anti-Obesity Agents. <i>Journal of Korean Diabetes</i> , 2015 , 16, 260	0.1
331	Liraglutide: an injectable option for the management of obesity. 2015 , 49, 938-44	14
330	3 Medical Management of Obesity. 2015 , 15-38	
329	Obesity Education Strategies for Cancer Prevention in Women's Health. 2015 , 4, 249-258	5
328	European Guidelines for Obesity Management in Adults. 2015 , 8, 402-24	509
327	Why are anti-obesity drugs stigmatized?. 2015 , 14, 185-9	13
326	New medications for treatment of obesity: metabolic and cardiovascular effects. 2015 , 31, 142-52	41
325	Drug treatment of obesity: current status and future prospects. 2015 , 26, 89-94	68
324	Improvement in chronic low back pain in an obese patient with topiramate use. 2015 , 29, 140-3	1
323	ANTI-OBESITY PHARMACOTHERAPY AND THE POTENTIAL FOR PREVENTING PROGRESSION FROM PREDIABETES TO TYPE 2 DIABETES. 2015 , 21, 634-44	6
322	Recommendations for obesity management and prevention have come a long way. 2015 , 39, 89-90	1
321	Next generation of weight management medications: implications for diabetes and CVD risk. 2015 , 17, 35	13
320	The New Era of Drug Therapy for Obesity: The Evidence and the Expectations. 2015 , 75, 935-45	37
319	Neural control of energy balance: translating circuits to therapies. 2015 , 161, 133-145	149

318	Combination phentermine and topiramate extended release in the management of obesity. 2015 , 16, 1263-74	18
317	Efficacy and safety of beloranib for weight loss in obese adults: a randomized controlled trial. 2015 , 17, 566-572	44
316	Treatment of obesity in 2015. 2015 , 35, 81-92	31
315	Simultaneous determination of phentermine and topiramate in human plasma by liquid chromatography-tandem mass spectrometry with positive/negative ion-switching electrospray ionization and its application in pharmacokinetic study. 2015 , 107, 444-9	9
314	Medications for weight loss. 2015 , 22, 91-7	13
313	Revisiting weight reduction and management in the diabetic patient: Novel therapies provide new strategies. 2015 , 127, 480-93	5
312	Advances in the Science, Treatment, and Prevention of the Disease of Obesity: Reflections From a Diabetes Care Editors' Expert Forum. 2015 , 38, 1567-82	133
311	Development of a Weighted Cardiometabolic Disease Staging (CMDS) System for the Prediction of Future Diabetes. 2015 , 100, 3871-7	19
310	Pharmacotherapy for the management of obesity. 2015 , 64, 1376-85	72
309	Pharmacotherapy for the treatment of obesity. 2015 , 418 Pt 2, 173-83	23
308	Synthesis and biological evaluation of novel chiral diazepine derivatives as bombesin receptor subtype-3 (BRS-3) agonists incorporating an antedrug approach. 2015 , 23, 89-104	13
307	A rationally designed monomeric peptide triagonist corrects obesity and diabetes in rodents. 2015 , 21, 27-36	363
306	Obesity. 2016 , 1633-1659	5
305	Unimolecular Polypharmacy for Treatment of Diabetes and Obesity. 2016 , 24, 51-62	153
304	Long-term effects of weight-reducing drugs in people with hypertension. 2016 , 3, CD007654	31
303	AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY COMPREHENSIVE CLINICAL PRACTICE GUIDELINES FOR MEDICAL CARE OF PATIENTS WITH OBESITY. 2016 , 22 Suppl 3, 1-203	557
302	CONSENSUS STATEMENT BY THE AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY ON THE COMPREHENSIVE TYPE 2 DIABETES MANAGEMENT ALGORITHM--2016 EXECUTIVE SUMMARY. 2016 , 22, 84-113	333
301	Maximizing retention in long-term clinical trials of a weight loss agent: use of a dietitian support team. 2016 , 2, 256-265	7

300	Pharmacologic Approaches to Weight Management: Recent Gains and Shortfalls in Combating Obesity. 2016 , 18, 36	9
299	An update on naltrexone/bupropion extended-release in the treatment of obesity. 2016 , 17, 2235-2242	6
298	Pharmacotherapy for Obesity. 2016 , 45, 521-38	26
297	Drugs to treat obesity: do they work?. 2016 , 92, 401-6	8
296	Weight maintenance: challenges, tools and strategies for primary care physicians. 2016 , 17, 81-93	49
295	Beyond Traditional Management: The Use of Medications in the Treatment of Obesity. 2016 , 231-260	
294	Pharmacological management of obesity in patients with type 2 diabetes. 2016 , 11, 415-423	
293	Obesity: Presentations and Management Options. 2016 , 231-236	
292	Cardiovascular Effects of the New Weight Loss Agents. 2016 , 68, 849-59	16
291	Safety and tolerability review of lorcaserin in clinical trials. 2016 , 6, 285-95	22
290	Common medications used by patients with type 2 diabetes mellitus: what are their effects on the lipid profile?. 2016 , 15, 95	39
289	Successful weight reduction and maintenance by using a smartphone application in those with overweight and obesity. 2016 , 6, 34563	59
288	Pharmacological management of nonalcoholic fatty liver disease. 2016 , 65, 1183-95	70
287	The 10(th) Annual Cardiometabolic Health Congress General Session Highlights. 2016 , 128 Suppl 1, 1-10	1
286	Obesity and diabetes mellitus in the Arab world. 2016 , 11, 301-309	13
285	Role of Bupropion Plus Naltrexone for the Management of Obesity. 2016 , 32, 125-132	1
284	Association of Pharmacological Treatments for Obesity With Weight Loss and Adverse Events: A Systematic Review and Meta-analysis. 2016 , 315, 2424-34	402
283	Prevention of type 2 Diabetes Mellitus: Potential of pharmacological agents. 2016 , 30, 357-71	11

282	Health-related quality of life in two randomized controlled trials of phentermine/topiramate for obesity: What mediates improvement?. 2016 , 25, 1237-44	12
281	Pharmacotherapy of Obesity and Metabolic Syndrome. 2016 , 797-809	
280	Pharmacotherapy in Conjunction with a Diet and Exercise Program for the Treatment of Weight Recidivism or Weight Loss Plateau Post-bariatric Surgery: a Retrospective Review. 2016 , 26, 452-8	51
279	Effects of canagliflozin on body weight and body composition in patients with type 2 diabetes over 104 weeks. 2016 , 128, 371-80	47
278	Weight management in obesity - past and present. 2016 , 70, 206-17	57
277	Past, Present, and Future of Pharmacologic Therapy in Obesity. 2016 , 43, 61-7, viii	14
276	A Comparison of New Pharmacological Agents for the Treatment of Obesity. 2016 , 50, 376-88	16
275	Management of obesity. 2016 , 387, 1947-56	461
274	Pharmacological Management. 2016 , 45-51	
273	Obesity context of type 2 diabetes and medication perspectives. 2016 , 13, 91-96	1
272	FDA-Approved Anti-Obesity Drugs in the United States. 2016 , 129, 879.e1-6	83
271	Position of the Academy of Nutrition and Dietetics: Interventions for the Treatment of Overweight and Obesity in Adults. 2016 , 116, 129-147	154
270	The GLP-1 agonist, liraglutide, as a pharmacotherapy for obesity. 2016 , 7, 92-107	27
269	Bariatric Left Gastric Artery Embolization for the Treatment of Obesity: A Review of Gut Hormone Involvement in Energy Homeostasis. 2016 , 206, 202-10	17
268	Extracellular vesicles: Pharmacological modulators of the peripheral and central signals governing obesity. 2016 , 157, 65-83	20
267	Current Perspectives on Long-term Obesity Pharmacotherapy. 2016 , 40, 184-91	15
266	Exploratory Literature Meta-Analysis to Characterize the Relationship Between Early and Longer Term Body Weight Loss for Antiobesity Compounds. 2017 , 57, 52-63	3
265	Practical Use of Pharmacotherapy for Obesity. 2017 , 152, 1765-1779	44

264	Pediatric Obesity-Assessment, Treatment, and Prevention: An Endocrine Society Clinical Practice Guideline. 2017 , 102, 709-757		485
263	A systematic review and narrative synthesis of interventions for uncomplicated obesity: weight loss, well-being and impact on eating disorders. 2017 , 5, 15		30
262	Cardiometabolic Disease Staging Predicts Effectiveness of Weight-Loss Therapy to Prevent Type 2 Diabetes: Pooled Results From Phase III Clinical Trials Assessing Phentermine/Topiramate Extended Release. 2017 , 40, 856-862		18
261	Tailoring pharmacotherapy to specific eating behaviours in obesity: Can recommendations for personalised therapy be made from the current data?. 2017 , 54, 715-725		13
260	Coadministration of lorcaserin and phentermine for weight management: A 12-week, randomized, pilot safety study. <i>Obesity</i> , 2017 , 25, 857-865	8	30
259	Impurity Control in Topiramate with High Performance Liquid Chromatography. 2017 , 379-392		2
258	Epidemiology of Obesity and Pharmacologic Treatment Options. 2017 , 32, 441-462		15
257	Pharmacotherapy of Obesity: Clinical Trials to Clinical Practice. 2017 , 17, 34		28
256	Regulation of visceral and epicardial adipose tissue for preventing cardiovascular injuries associated to obesity and diabetes. 2017 , 16, 44		98
255	Dapagliflozin once daily plus exenatide once weekly in obese adults without diabetes: Sustained reductions in body weight, glycaemia and blood pressure over 1 year. 2017 , 19, 1276-1288		37
254	CONSENSUS STATEMENT BY THE AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY ON THE COMPREHENSIVE TYPE 2 DIABETES MANAGEMENT ALGORITHM - 2017 EXECUTIVE SUMMARY. 2017 , 23, 207-238		302
253	Coadministration of Canagliflozin and Phentermine for Weight Management in Overweight and Obese Individuals Without Diabetes: A Randomized Clinical Trial. 2017 , 40, 632-639		53
252	Pharmacotherapy for Weight Management in the VHA. 2017 , 32, 70-73		12
251	Percutaneous Gastrostomy Device for the Treatment of Class II and Class III Obesity: Results of a Randomized Controlled Trial. 2017 , 112, 447-457		111
250	Proportional Feedback Control of Energy Intake During Obesity Pharmacotherapy. <i>Obesity</i> , 2017 , 25, 2088-2091	8	13
249	Past, present and future of pharmacotherapy for obesity. 2017 , 29, 256-264		2
248	Obesity management among patients with type 2 diabetes and prediabetes: a focus on lifestyle modifications and evidence of antiobesity medications. 2017 , 12, 303-313		3
247	Current and emerging pharmacotherapies for obesity in Australia. 2017 , 11, 501-521		7

246	Translational Modeling to Guide Study Design and Dose Choice in Obesity Exemplified by AZD1979, a Melanin-concentrating Hormone Receptor 1 Antagonist. 2017 , 6, 458-468	3
245	Obesity and Weight Loss in Idiopathic Intracranial Hypertension: A Narrative Review. 2017 , 37, 197-205	42
244	Weight management in adults. 2017 , 139-259	
243	Past, present and future of pharmacotherapy for obesity. 2017 , 29, 256-264	
242	Combination therapy for obesity. 2017 , 31, 1503-1508	20
241	Neural circuits of eating behaviour: Opportunities for therapeutic development. 2017 , 31, 1388-1402	9
240	Cardiovascular Outcome Trials of Diabetes and Obesity Drugs: Implications for Conditional Approval and Early Phase Clinical Development. 2017 , 31, 399-421	2
239	The burden of obesity in the current world and the new treatments available: focus on liraglutide 3.0 mg. 2017 , 9, 44	33
238	A Guide to Medications Inducing Salivary Gland Dysfunction, Xerostomia, and Subjective Sialorrhea: A Systematic Review Sponsored by the World Workshop on Oral Medicine VI. 2017 , 17, 1-28	131
237	Obesity: Current and potential pharmacotherapeutics and targets. 2017 , 170, 116-147	88
236	Care of the Obese Patient. 2017 , 699-707	
235	Safety assessment of combination therapies in the treatment of obesity: focus on naltrexone/bupropion extended release and phentermine-topiramate extended release. 2017 , 16, 27-39	24
234	Pharmabiotics as an Emerging Medication for Metabolic Syndrome and Its Related Diseases. 2017 , 22,	14
233	Obesity Pharmacotherapy in Patients With Type 2 Diabetes. 2017 , 30, 250-257	17
232	Diet and Weight Management. 2018 , 71-82	
231	Medically Supervised Weight Loss Programs. 2018 , 211-223	
230	Rationale for Utilization of Obesity Pharmacotherapy in the Active Duty Population. 2018 , 183, 45-50	2
229	Safety and tolerability of new-generation anti-obesity medications: a narrative review. 2018 , 130, 173-182	64

228	Updates on obesity pharmacotherapy. 2018 , 1411, 106-119		38
227	The safety of pharmacologic treatment for pediatric obesity. 2018 , 17, 379-385		23
226	Benefits and Harms in Pivotal Trials of Oral Centrally Acting Antiobesity Medicines: A Systematic Review and Meta-Analysis. <i>Obesity</i> , 2018 , 26, 513-521	8	3
225	Obesity: Pathophysiology and Management. 2018 , 71, 69-84		192
224	Effects of Weight-Loss Medications on Cardiometabolic Risk Profiles: A Systematic Review and Network Meta-analysis. 2018 , 154, 1309-1319.e7		39
223	The Science of Obesity Management: An Endocrine Society Scientific Statement. 2018 , 39, 79-132		304
222	Pharmacotherapy for Patients with Obesity. 2018 , 64, 118-129		29
221	Current pharmacotherapy for obesity. 2018 , 14, 12-24		192
220	Psychopharmacological advances in eating disorders. 2018 , 11, 95-108		49
219	Progress and challenges in anti-obesity pharmacotherapy. 2018 , 6, 237-248		118
218	Maintenance of Lost Weight and Long-Term Management of Obesity. 2018 , 102, 183-197		170
217	Obesity Pharmacotherapy. 2018 , 102, 135-148		68
216	Observational Comparative Effectiveness of Pharmaceutical Treatments for Obesity within the Veterans Health Administration. 2018 , 38, 19-28		12
215	Drug Treatment of Obesity: From Bench to Bedside. 2018 ,		
214	Phentermine: A Systematic Review for Plastic and Reconstructive Surgeons. 2018 , 81, 503-507		4
213	Reprint of: Healthy Weight and Obesity Prevention: JACC Health Promotion Series. 2018 , 72, 3027-3052		20
212	The Role of Weight Management in the Treatment of Adult Obstructive Sleep Apnea. An Official American Thoracic Society Clinical Practice Guideline. 2018 , 198, e70-e87		78
211	Healthy Weight and Obesity Prevention: JACC Health Promotion Series. 2018 , 72, 1506-1531		172

210	Anorectic efficacy and safety of the diethylpropion-topiramate combination in rats. 2018 , 79, 225-233	3
209	Behavioral and Pharmacotherapy Weight Loss Interventions to Prevent Obesity-Related Morbidity and Mortality in Adults: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force. 2018 , 320, 1172-1191	173
208	Role of Cannabinoids in Obesity. 2018 , 19,	40
207	Medical Management of Obesity. 2018 , 379-402	
206	Addressing Obesity in Clinical Gynecology Practice. 2018 , 61, 10-26	3
205	Why Weight? An Analytic Review of Obesity Management, Diabetes Prevention, and Cardiovascular Risk Reduction. 2018 , 20, 39	15
204	New treatment modalities for obesity. 2018 , 32, 535-549	22
203	Lifestyle Changes and Weight Loss: Effects in PCOS. 2018 ,	0
202	CONSENSUS STATEMENT BY THE AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY ON THE COMPREHENSIVE TYPE 2 DIABETES MANAGEMENT ALGORITHM - 2018 EXECUTIVE SUMMARY. 2018 , 24, 91-120	321
201	Centrally Acting Agents for Obesity: Past, Present, and Future. 2018 , 78, 1113-1132	52
200	Combination of Phentermine/Topiramate Er and Liraglutide 3 Mg for Intensive Therapy of Severe Obesity & T2Dm: A Case Series and Brief Review. 2018 , 4, e482-e486	1
199	Pharmacological interventions for obesity: current and future targets. 2018 , 5, 202-211	8
198	Persistence of newer anti-obesity medications in a real-world setting. 2018 , 143, 348-356	16
197	Weight Loss Strategies for Treatment of Obesity: Lifestyle Management and Pharmacotherapy. 2018 , 61, 246-252	38
196	Treatment: New Drugs. 2019 , 464-472	
195	Precision medicine in adult and pediatric obesity: a clinical perspective. 2019 , 10, 2042018819863022	12
194	Obesity and pancreatic cancer: An update of epidemiological evidence and molecular mechanisms. 2019 , 19, 941-950	22
193	THE BENEFIT OF SHORT-TERM WEIGHT LOSS WITH ANTI-OBESITY MEDICATIONS IN REAL-WORLD CLINICAL PRACTICE. 2019 , 25, 1022-1028	4

192	Safety and Efficacy of Weight-Loss Pharmacotherapy in Persons Living with HIV: A Review of the Literature and Potential Drug-Drug Interactions with Antiretroviral Therapy. 2019 , 39, 1204-1215	4
191	Identification and Management of Cardiometabolic Risk after Spinal Cord Injury. 2019 , 42, 643-677	25
190	Pharmaceutical approaches to weight management: behavioural mechanisms of action. 2019 , 12, 26-32	1
189	Obesity an overview: Genetic conditions and recent developments in therapeutic interventions. 2019 , 13, 2112-2120	7
188	Incorporating Weight Loss Medications Into Hepatology Practice for Nonalcoholic Steatohepatitis. 2019 , 70, 1443-1456	8
187	Pathobiological mechanisms underlying metabolic syndrome (MetS) in chronic obstructive pulmonary disease (COPD): clinical significance and therapeutic strategies. 2019 , 198, 160-188	39
186	Effects of liraglutide plus phentermine in adults with obesity following 1 year of treatment by liraglutide alone: A randomized placebo-controlled pilot trial. 2019 , 96, 83-91	4
185	Safety and Effectiveness of Longer-Term Phentermine Use: Clinical Outcomes from an Electronic Health Record Cohort. <i>Obesity</i> , 2019 , 27, 591-602	8 24
184	Pharmacotherapy of Obesity: Limits and Perspectives. 2019 , 19, 349-364	7
183	CONSENSUS STATEMENT BY THE AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY ON THE COMPREHENSIVE TYPE 2 DIABETES MANAGEMENT ALGORITHM - 2019 EXECUTIVE SUMMARY. 2019 , 25, 69-100	191
182	Obesity. 2019 , 170, ITC33-ITC48	19
181	Evolution of Endoscopic Bariatric Devices: From Development to Practice. 2019 , 114, 679-683	3
180	Current Treatments on Obesity. 2019 , 19, 171	2
179	Pharmacotherapy for Weight Management. 2019 , 395-411	1
178	Precision Medicine in Weight Loss and Healthy Living. 2019 , 62, 15-20	20
177	Medications Indicated for Chronic Weight Management. 2019 , 401-424	
176	Treating obesity in patients with cardiovascular disease: the pharmacotherapeutic options. 2019 , 20, 585-593	9
175	Pharmacologic Agents Chapter for Abdominal Obesity. 2019 , 51-66	1

174	Cardiovascular Safety During and After Use of Phentermine and Topiramate. 2019 , 104, 513-522	18
173	Pharmacotherapy of obesity: Available medications and drugs under investigation. 2019 , 92, 170-192	98
172	Pathophysiology and Individualized Treatment of Hypothalamic Obesity Following Craniopharyngioma and Other Suprasellar Tumors: A Systematic Review. 2019 , 40, 193-235	41
171	Obesity and Therapeutic Approaches to Weight Loss. 2019 , 71-85	
170	Choosing a Medication. 2019 , 105-119	
169	Hypertension in Obesity: Novel Insights. 2020 , 16, 30-36	4
168	Meal patterns after bariatric surgery in mice and rats. <i>Appetite</i> , 2020 , 146, 104340	4-5 3
167	Anorectic state of obesity medications in the United States. Are leaner times ahead?. 2020 , 21, 167-172	2
166	Pharmacotherapy in obesity: a systematic review and meta-analysis of randomized controlled trials of anti-obesity drugs. 2020 , 13, 53-64	39
165	Reprint of: Recent Updates on Obesity Treatments: Available Drugs and Future Directions. 2020 , 447, 191-215	6
164	The risk of cardiovascular complications with current obesity drugs. 2020 , 19, 1095-1104	6
163	Weight loss: Lifestyle interventions and pharmacotherapy. 2020 , 219-234	
162	Overview of bariatric and metabolic endoscopy interventions. 2020 , 13, 2631774520935239	2
161	Medical Weight-Loss Outcomes in Patients Receiving Concomitant Psychotropic Medication: A Retrospective Cohort Study. <i>Obesity</i> , 2020 , 28, 1671-1677	8 2
160	Recent Updates on Obesity Treatments: Available Drugs and Future Directions. 2020 , 437, 215-239	23
159	Obesity Treatment: A Focus on Pharmacotherapy of Weight Management. 2020 , 39, 121-127	1
158	Medications Available for Weight Reduction in Elective Total Joint Arthroplasty. 2020 , 8, e0123	0
157	Medications for the treatment of obesity in adolescents. 2020 , 11, 2042018820918789	11

156	Pharmacological therapies to address obesity in type 1 diabetes. 2020 , 27, 194-206	3
155	Cardiometabolic Disease and Dysfunction Following Spinal Cord Injury: Origins and Guideline-Based Countermeasures. 2020 , 31, 415-436	11
154	Modern pharmacological treatment of obese patients. 2020 , 11, 2042018819897527	28
153	CONSENSUS STATEMENT BY THE AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY ON THE COMPREHENSIVE TYPE 2 DIABETES MANAGEMENT ALGORITHM -. 2020 , 26, 107-139	206
152	The limits and challenges of antiobesity pharmacotherapy. 2020 , 21, 1319-1328	9
151	Pharmacological treatment of eating disorders, comorbid mental health problems, malnutrition and physical health consequences. 2021 , 217, 107667	13
150	Pharmacotherapy for Weight Loss in Cirrhosis and Liver Transplantation: Translating the Data and Underused Potential. 2021 , 73, 2051-2062	1
149	Diabesity: the combined burden of obesity and diabetes on heart disease and the role of imaging. 2021 , 18, 291-304	33
148	Best Practices in the Management of Overweight and Obesity. 2021 , 105, 149-174	18
147	Strategies to Treat Obesity in Patients With CKD. 2021 , 77, 427-439	19
146	Clinical Impact of Weight-Loss Pharmacotherapy in Patients with Atherosclerotic Cardiovascular Disease. 2021 , 21, 271-281	3
145	Pharmacologie de l'obésité vers de nouvelles options. 2021 , 663-672	
144	Obesity: Medical and Surgical Treatment. 2021 , 131-175	
143	Comparing effectiveness of fat burners and thermogenic supplements to diet and exercise for weight loss and cardiometabolic health: Systematic review and meta-analysis. 2021 , 27, 445-459	0
142	Long-term effects of weight-reducing drugs in people with hypertension. 2021 , 1, CD007654	2
141	Extrapolation from Clinical Trial to Practice: Current Pharmacotherapy on Obesity. 2021 , 125-148	
140	Epigenetic Regulation of Adipogenesis in Development of Metabolic Syndrome. 2020 , 8, 619888	12
139	Anti-Obesity Drugs: Long-Term Efficacy and Safety: An Updated Review. 2021 , 39, 208-221	21

138	Medikamentöse Therapie der Adipositas. 2021 , 16, 16-21		
137	Binge-Eating Disorder and Type 2 Diabetes: A Review. 2021 , 27, 158-164		4
136	An update on pharmacotherapeutic strategies for obesity. 2021 , 22, 1305-1318		3
135	Handschuhe, Helm und Schweregefühl Das T4-Syndrom. 2021 , 19, 24-29		
134	Phentermine-Induced Acute Kidney Injury Secondary to Uncontrolled Hypertension in a Patient with Weight Regain Post-bariatric Surgery. 2021 , 31, 3874-3879		1
133	A Nephrologist Perspective on Obesity: From Kidney Injury to Clinical Management. 2021 , 8, 655871		7
132	Efficacy and Safety of Phentermine/Topiramate in Adults with Overweight or Obesity: A Systematic Review and Meta-Analysis. <i>Obesity</i> , 2021 , 29, 985-994	8	1
131	Weight Loss and Maintenance Related to the Mechanism of Action of Glucagon-Like Peptide 1 Receptor Agonists. 2021 , 38, 2821-2839		10
130	Cardiovascular safety of long-term anti-obesity drugs in subjects with overweight or obesity: a systematic review and meta-analysis. 2021 , 77, 1611-1621		2
129	In search of an ideal drug for safer treatment of obesity: The false promise of pseudoephedrine. 2021 , 1		0
128	Five-Year Outcomes of Endoscopic Sleeve Gastroplasty for the Treatment of Obesity. 2021 , 19, 1051-1057.e2		30
127	Obesity in Patients with Type 1 Diabetes: Links, Risks and Management Challenges. 2021 , 14, 2807-2827		5
126	Pharmacotherapeutic options for weight regain after bariatric surgery. 2021 , 19, 524-541		
125	Pharmacotherapy in Childhood Obesity. 2021 ,		0
124	Management of Obesity and Nonalcoholic Fatty Liver Disease: A Literature Review. 2021 , 41, 435-447		1
123	Pharmacotherapy of obesity: An update. 2021 , 169, 105649		7
122	Medical and Surgical Obesity Treatments and Atherosclerosis: Mechanisms beyond Typical Risk Factors. 2021 , 23, 60		
121	New Incretin Combination Treatments under Investigation in Obesity and Metabolism: A Systematic Review. 2021 , 14,		3

120	Descriptive analysis of reported adverse events associated with anti-obesity medications using FDA Adverse Event Reporting System (FAERS) databases 2013-2020. 2021 , 1	0
119	Effects of Combined Oxytocin and Beta-3 Receptor Agonist (CL 316243) Treatment on Body Weight and Adiposity in Male Diet-Induced Obese Rats. 2021 , 12, 725912	4
118	Synthesis of (Jujube) Root Methanol Extract Loaded Functionalized Silver Nanoparticle (ZS-Ag-NPs); Physiochemical Characterization and Effect of ZS-Ag-NPs on Adipocyte Maturation, Adipokine and Vascular Smooth Muscle Cell Interaction. 2021 , 11,	2
117	Obesity-An Update on the Basic Pathophysiology and Review of Recent Therapeutic Advances. 2021 , 11,	1
116	Pharmacologic Weight Loss for Heart Failure With Preserved Ejection Fraction: Getting to the Core of the Problem. 2021 , 14, e008554	
115	Long-Term Efficacy and Safety of Anti-Obesity Treatment: Where Do We Stand?. 2021 , 10, 14-30	31
114	[Pharmacological treatment of obesity for Primary Care physicians]. 2019 , 45, 559-565	1
113	Treatment of Obesity in Mitigating Metabolic Risk. 2020 , 126, 1646-1665	18
112	CNS-targeting pharmacological interventions for the metabolic syndrome. 2019 , 129, 4058-4071	13
111	Identification and Management of Cardiometabolic Risk after Spinal Cord Injury: Clinical Practice Guideline for Health Care Providers. 2018 , 24, 379-423	41
110	Energy imbalance: obesity, associated comorbidities, prevention, management and public health implications. 2020 , 10, 146-161	3
109	Current Options for the Pharmacotherapy of Obesity. 2019 , 25, 2019-2032	2
108	Obesity: The New Global Epidemic Pharmacological Treatment, Opportunities and Limits for Personalized Therapy. 2020 , 20, 1232-1243	5
107	The role of psychobiological and neuroendocrine mechanisms in appetite regulation and obesity. 2012 , 6, 147-55	15
106	Therapies for obesity and medication-associated weight gain. 2013 , 51, 13-6	5
105	Comprehensive Review of Current and Upcoming Anti-Obesity Drugs. 2020 , 44, 802-818	17
104	Phentermine-topiramate: First combination drug for obesity. 2015 , 5, 157-8	17
103	Ciliochoroidal effusion in topiramate-induced bilateral acute angle closure glaucoma. 2019 , 67, 1466-1467	5

102	Treating morbid obesity in cirrhosis: A quest of holy grail. 2015 , 7, 2819-28	14
101	The Role of Anti-Obesity Medication in Prevention of Diabetes and Its Complications. 2019 , 28, 158-166	11
100	Current Long-Term Pharmacotherapies for the Management of Obesity. 2020 , 29, 99-109	3
99	Pharmacological Management of Obesity in Patients with Type 2 Diabetes: An Update. 2016 , 25, 121-128	2
98	Phentermine, sibutramine and affective disorders. 2013 , 11, 7-12	5
97	Oxytocin as an Anti-obesity Treatment. 2021 , 15, 743546	0
96	Treating the Chronic Disease of Obesity. 2021 , 105, 983-1016	1
95	Was it worth the weight? - Drug review on two new weight loss agents: lorcaserin (Belviq®) and phentermine/topiramate ER (Qsymia™). 2012 , 2, 144-151	
94	Current Management of Obesity in an Infertile Female-Recent Advances and Future Prospective Drugs.	0
93	Drugs for Weight Loss and Maintenance: Present and Future. 2014 , 225-245	
92	Effects of Obesity on OSA and Its Treatment. 2014 , 193-202	
91	Prescription Medications for the Treatment of Obesity. 2015 , 261-270	
90	Obesity: Genetics, Pathogenesis, Therapy. 2015 , 1-17	1
89	Medikamentöse Therapie der Adipositas. 2015 , 535-542	
88	Care of the Obese Patient. 2015 , 1-9	
87	The Doctor's Tool Kit: Pharmacotherapy for the Patient with Obesity. 2015 , 91-109	
86	Pharmacotherapy of Obesity and Metabolic Syndrome. 2015 , 1-16	
85	Safety of Anti-Obesity Drugs Approved for Long-Term Use. 2015 , 24, 17-27	6

- 84 Medical Management of Obesity. **2016**, 39-49
- 83 ORLISTAT AND PHENTERMINE IN WEIGHT LOSS IN SELECTED CZECH POPULATION. **2016**, 85, 13-18
- 82 Advances in Pharmacological Treatment of Pediatric Obesity. **2016**, 333-351
- 81 Individualizing Lifestyle Therapy for Patients with Obesity. **2016**, 22, 14-20
- 80 Obesity: Genetics, Pathogenesis, Therapy. **2017**, 1-17 1
- 79 Medications Indicated for Chronic Weight Management. **2017**, 1-24
- 78 Obesity: Genetics, Pathogenesis, and Therapy. **2017**, 607-622
- 77 Pharmacotherapy for Weight Loss. **2017**, 277-296
- 76 Weight Loss Medication in Bariatric Surgery. **2017**, 6, 1-5
- 75 Role of Pharmacotherapy in the Treatment of Pediatric Obesity and Its Comorbidities. **2018**, 613-627 1
- 74 Les traitements médicamenteux de l'obésité **2017**, 47, 304-309 1
- 73 Recent Advances in Anti-Obesity Agents. **2018**, 93, 501-508 7
- 72 Comparison of Valvulopathy Risk with Lorcaserin and Phenterminetopiramate for Weight Loss. **2019**, 14, 74-78
- 71 Morbid Obesity. **2020**, 23-29
- 70 Wegovy (semaglutide): a new weight loss drug for chronic weight management. **2021**, 8
- 69 Therapeutic Management of Obesity. **2021**, 323-339 1
- 68 An Update on Mendelian Forms of Obesity and their Personalized Treatments. **2020**, 207-219
- 67 Drugs for Weight Loss and Maintenance: Present and Future. **2014**, 225-245 0

66	Efficacy and safety of phentermine/topiramate in adults with overweight or obesity: A meta-analysis and systematic review.	
65	Pharmacotherapy in pediatric obesity: current evidence and landscape. 2021 , 28, 55-63	4
64	Obesity. 2021 , 267-278	
63	Phentermine/Topiramate extended-release capsules (qsymia) for weight loss. 2013 , 38, 446-52	7
62	New drug therapies for the treatment of overweight and obese patients. 2013 , 6, 423-30	8
61	Obesity Management: Clinical Review and Update of the Pharmacologic Treatment Options. 2016 , 33, 6-16	1
60	Energy imbalance: obesity, associated comorbidities, prevention, management and public health implications. 2020 , 10, 146-161	3
59	Effectiveness of anti-obesity medications approved for long-term use in a multidisciplinary weight management program: a multi-center clinical experience. 2021 ,	3
58	Long-acting amylin analogue for weight reduction. 2021 ,	1
57	Potential of Carbonic Anhydrase Inhibitors in the Treatment of Oxidative Stress and Diabetes. 2021 , 121-146	
56	Skin and obesity in childhood: an update. 2021 , 8, 311-323	1
55	Drugs for Treating Obesity. 2021 ,	3
54	Medical Management of Obesity as it Affects Reflux. 263451612110691	
53	Oxytocin as a potential pharmacological tool to combat obesity.. 2022 , e13106	0
52	New Horizons A New Paradigm for Treating to Target with Second-Generation Obesity Medications. 2021 ,	5
51	Pharmacological Treatment of Obesity. 2022 , 435-442	
50	Research Progress of Slimming Products and Their Pharmacological Mechanisms. 2022 , 11, 73-79	
49	Obesity and Diabetes. 2022 , 1-61	

48	What is clinically relevant weight loss for your patients and how can it be achieved? A narrative review.. 2022 ,			1
47	Benefits of weight loss of 10% or more in patients with overweight or obesity: A review.. <i>Obesity</i> , 2022 , 30, 802-840	8		3
46	Adjunctive Therapy, Including Pharmacotherapy. 2022 , 279-296			
45	Pharmacotherapy of obesity in complex diseases. 2021 , e12497			1
44	Clinical Evaluation, Lifestyle, and Pharmacological Management of Obesity. 2022 , 221-240			
43	Phentermine/Topiramate for the Treatment of Adolescent Obesity.			1
42	Utility of an experimental medicine model to evaluate efficacy, side-effects and mechanism of action of novel treatments for obesity and binge-eating disorder.. <i>Appetite</i> , 2022 , 106087	4.5		
41	An Overview On Treatment Modalities And Management Aspects For Obesity. <i>Current Nutrition and Food Science</i> , 2022 , 18,	0.7		
40	Pharmacological Management of Obesity: A Century of Expert Opinions in Cecil Textbook of Medicine. <i>American Journal of Therapeutics</i> , Publish Ahead of Print,			1
39	Longitudinal Changes of Body Weight According to Sex, Age and Metabolic Parameters in Korean Morbid Obese Patients after Sleeve Gastrectomy: 12-Month Retrospective Cohort Study. <i>Korean Journal of Family Practice</i> , 2022 , 12, 185-192	0.4		
38	Medical Weight Management: A Multidisciplinary Approach.			
37	Recent Advances in Anti-Obesity Drugs. <i>Journal of Korean Diabetes</i> , 2022 , 23, 113-127	0.1		1
36	Anti-obesity weight loss medications: Short-term and long-term use. <i>Life Sciences</i> , 2022 , 306, 120825	6.8		1
35	Medikamentöse Therapie der Adipositas. 2022 , 603-609			
34	Pharmacologic treatment of obesity. 2022 , 65, 408-416			
33	Pharmacotherapy in obesity: the current state and the near future. 2022 , 65, 514-531			
32	WITHDRAWN: American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan 2022 Update. 2022 ,			8
31	Medical and Surgical Treatment of Obesity. 2022 ,			

30	Medical Management of Obesity. 2021 , 1-19	0
29	Management of obesity and related inflammatory disorders. 2023 , 233-262	0
28	The use of virtual visits for obesity pharmacotherapy in patients with overweight or obesity compared with in-person encounters.	0
27	Efficacy and safety of traditional chinese medicine treatment for overweight and obese individuals: A systematic review and meta-analysis. 13,	0
26	Medical treatment of weight loss in children and adolescents with obesity. 2022 , 185, 106471	2
25	Hypertension Related to Obesity: Pathogenesis, Characteristics and Factors for Control. 2022 , 23, 12305	0
24	AGA Clinical Practice Guideline on Pharmacological Interventions for Adults With Obesity. 2022 , 163, 1198-1225	1
23	Non-Surgical Management of Obesity. 2022 , 33-45	0
22	New therapies for obesity.	2
21	Effect of the Melanocortin 4-Receptor Ile269Asn Mutation on Weight Loss Response to Dietary, Phentermine and Bariatric Surgery Interventions. 2022 , 13, 2267	0
20	A comparison between weight loss outcomes with anti-obesity medications before and during Covid-19 pandemic at a tertiary weight management center. 2022 , 4, 100046	0
19	Semaglutide 2.4 Mg for the Management of Overweight and Obesity: Systematic Literature Review and Meta-Analysis. Volume 15, 3961-3987	0
18	Obesity and diabetes: the final frontier.	1
17	Comparing and contrasting different herbal products intended for the management of obesity approved in the Palestinian markets. 2023 , 23,	0
16	Weight Loss From Combination Anti-Obesity Medication Regimens Can Approach that Achieved From Bariatric Surgery. 2022 , 1,	0
15	The Long Way of Oxytocin from the Uterus to the Heart in 70 Years from Its Discovery. 2023 , 24, 2556	0
14	The effects of weight-lowering pharmacotherapies on physical activity, function and fitness: A systematic review and meta-analysis of randomized controlled trials.	0
13	A Multi-Ingredient Supplement Protects against Obesity and Infertility in Western Diet-Fed Mice. 2023 , 15, 611	0

12	Medical Management of Obesity. 2023 , 63-81	0
11	Contemporary medical, device, and surgical therapies for obesity in adults. 2023 , 401, 1116-1130	1
10	Obesity and Aging. 2023 , 52, 317-339	0
9	Efficacy and safety of the ghrelin-O-acyltransferase inhibitor BI 1356225 in overweight/obesity: Data from two Phase I, randomised, placebo-controlled studies. 2023 , 143, 155550	0
8	Pharmacological Support for the Treatment of Obesity Present and Future. 2023 , 11, 433	1
7	Obesity Pharmacotherapy: a Review of Current Practices and Future Directions. 2023 , 21, 27-47	0
6	The Case for Bariatric Surgery in Patients with Class 1 Obesity.	0
5	Pharmacotherapy of obesity: an update on the available medications and drugs under investigation. 2023 , 58, 101882	0
4	Evaluation and Treatment of Obesity and Its Comorbidities: 2022 Update of Clinical Practice Guidelines for Obesity by the Korean Society for the Study of Obesity. 2023 , 32, 1-24	0
3	Cost-effectiveness analysis of five anti-obesity medications from a US payer's perspective. 2023 ,	0
2	Pharmacologic management for polycystic ovary syndrome: Weight loss. 2024 , 122-129	0
1	Medications for obesity management: Effectiveness and value. 2023 , 29, 569-575	0